Gabapentinoids and the risk of severe respiratory events in patients with chronic obstructive pulmonary disease

加巴喷丁类药物与慢性阻塞性肺疾病患者发生严重呼吸系统事件的风险

• 批准号: 444929
• 负责人: Renoux Christel
• 金额: $ 8.74万
• 依托单位: Lady Davis Institute for Medical Research (Mtl)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-04-01 至 2023-04-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=444929&lang=en
• 关键词: Cohort; Copd; Drug Safety; Gabapentinoids; Pharmacoepidemiology

Gabapentinoids (GABAs) are drugs that are approved for the treatment of seizure and certain types of pain. In the last decade, a sharp increase in the prescription of these drugs, particularly in combination with opioids, has been observed in North Americ

Gabapentinoids（加巴斯）是被批准用于治疗癫痫发作和某些类型疼痛的药物。在过去十年中，据观察，在北美，这些药物的处方急剧增加，特别是与类阿片合用的处方。